Özlem Türeci to Stomach Neoplasms
This is a "connection" page, showing publications Özlem Türeci has written about Stomach Neoplasms.
Connection Strength
0.483
-
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer. 2018 09; 100:17-26.
Score: 0.483